Business
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTX...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Granted Trademark \"KNOW YOUR HEALTH\" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce that the Government of Japan has granted registration of its trademark \"KNOW YOUR HEALTH\", under International Registration No. 1744775, covering Classes 1, 5, and 42.This registration secures Hemostemix's rights in Japan for the mark Know Your Health and its design, reinforcing the Company's intellectual property position and global branding strategy across regenerative medicine, biotechnology, and personalized health innovation.Trademark Grant DetailsRegistration Number: International Registration No. 1744775Mark: KNOW YOUR HEALTH Classes Covered:Class 1: Chemicals and reagents for scientific and medical research, including stem cell preparations for use in regenerative medicine.Class 5: Pharmaceutical and biological preparations, including autologous stem cell compositions for the treatment of peripheral vascular disease, critical limb ischemia, peripheral neuropathy, Class I-IV heart disease including angina, ischemic cardiomyopathy, and dilated cardiomyopathy, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary hypertension, and other diseases of ischemia.Class 42: Scientific, clinical, and technological services in the field of regenerative medicine, including design, research, and development of cell-based therapies, diagnostics, and personalized health data platforms.Issuing Authority: Japanese Patent Office (via WIPO Madrid System)Strategic SignificanceAlignment with Clinical Programs: The trademark encompasses therapeutic areas currently available under right to try legislation or special access programs in various jurisdictions including Japan, of an ACP-01 treatment for patients suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non...